Background: The response of primary breast cancer to chemotherapy is usually expressed either as a pathological complete remission (pCR) or as 'no pCR'. A more quantitative measure is called for.
introduction
Neoadjuvant systemic therapy has become a widely employed treatment option for operable breast cancer. It is equally effective as similar drug therapy following local treatment in terms of recurrence-free and overall survivals and it allows breast-sparing surgery in some patients who would otherwise have needed a mastectomy [1, 2] . Furthermore, neoadjuvant chemotherapy is attractive since the response of the primary tumor to the selected drug regimen can be monitored. Breast cancer is a remarkably polymorphic disease and lack of response or even progression may occur with any drug regimen. At least in theory, prolonged treatment with nonefficacious drugs could be avoided by response monitoring. In case of insufficient shrinkage (or more sophisticated parameters of response), chemotherapy could be discontinued in favor of surgery or the chemotherapy could be changed to a (presumably) non-cross resistant regimen. Early trials of such strategies have not met with success [3] , but the arrival of new drugs, often with novel mechanisms of action, and modern imaging techniques hold the promise that this approach could become valuable in the near future [4] .
In studies comparing primary chemotherapy to the same chemotherapy after surgery, pathological complete remission (pCR) after chemotherapy appeared to be a strong prognostic marker of recurrence-free and overall survivals [5, 6] . As a result, the achievement of a pCR has become the primary objective of many neoadjuvant chemotherapy studies. In the most frequent subtype of breast cancer, however, estrogen receptor-positive (ER+) HER2-negative (HER2) disease, pCRs following neoadjuvant therapy are rare and occur in only 5% of cases [2] . This almost certainly reflects a lesser degree of chemotherapy sensitivity of 'luminal' breast cancer. There is no doubt, however, that chemotherapy is-on average-beneficial in this tumor type: the majority of patients show clear and sometimes dramatic shrinkage of their tumors and the ability of chemotherapy to reduce recurrence and breast cancer deaths in this patient group has been demonstrated beyond any doubt [7] . Thus, the binary response classification after neoadjuvant therapy in 'pCR' and 'no pCR' almost certainly sacrifices valuable response information to simplicity and may thus be misleading.
One interesting approach to deal with this problem is the estimation of residual disease burden [8] , in which careful pathological examination of the resection specimen aims to quantitatively assess the tumor mass that remains after systemic therapy. The residual tumor burden has been shown to be a prognostic marker. It does not, however, take the initial tumor volume into account. Clearly, tumors that are small to begin with are associated with smaller residual disease burdens, even in the absence of a good chemotherapy response. Conversely, large tumors may respond well to chemotherapy without approaching a complete remission. In addition, the residual disease burden estimate requires a careful pathology review, preferably by a single expert pathologist, that may not always be practical in multicenter settings.
To compare the efficacy of different therapeutic regimens in the neoadjuvant setting and to evaluate the sensitivity and resistance of certain tumor types to a specific drug, we developed a simple scoring system, the 'neoadjuvant response index' (NRI) to estimate the degree of downstaging achieved by drug therapy. The calculation method always leads to a score between 0 and 1. A score of 0 represents no response (or even progression in exceptional cases), while a score of 1 indicates a pCR of both the breast tumor and the axilla. We illustrate the use of this NRI and show that breast cancers satisfying the definition of 'highly endocrine responsive' respond less to neoadjuvant chemotherapy than those that are 'incompletely endocrine responsive'.
patients, materials and methods patients
Between October 2004 and October 2008, patients receiving preoperative chemotherapy were included in the present study. All either participated in clinical studies of neoadjuvant chemotherapy [9] that had been approved by the institutional review board or received neoadjuvant chemotherapy according to the standard arm of one of these studies off protocol. Eligibility for neoadjuvant chemotherapy on or off protocol included (i) microscopically confirmed stage II or III epithelial breast cancer; (ii) diameter of the primary tumor at least 3 cm [as measured by magnetic resonance imaging (MRI) or ultrasound] and/or (iii) fine-needle aspiration (FNA) or sentinel node-proven axillary node metastasis. The standard preparatory investigations included (i) core biopsies of the primary tumor; (ii) ultrasound examination of the ipsilateral axilla and periclavicular region with FNA of any suspected lymph node metastasis; (iii) a prechemotherapy sentinel node procedure in case of a clinically negative axilla and (iv) contrast-enhanced MRI of the breast, to be repeated after three courses of chemotherapy or after 8 weeks of chemotherapy in combination with trastuzumab (Roche, Woerden, The Netherlands) in the case of HER2-positive (HER+) disease.
The chemotherapy consisted of calculation of the NRI
The NRI was calculated from a breast response score and an axillary response score.
The initial staging in clinical stages T4, T3, T2, T1 or Tx was based on contrast-enhanced MRI. In case of multicentric disease, the size of the tumor was defined as the maximum diameter of the region with tumor foci. If an MRI examination was not available, the maximum tumor diameter by ultrasound was used. Following surgery, the diameter of the residual tumor as indicated by the pathology report was taken to determine the T-stage. A pCR of the breast (pCR breast) was defined as the complete absence of invasive tumor cells at microscopy, irrespective of the presence of carcinoma in situ. A 'near-pCR breast' meant that only a few scattered tumor cells remained or that the residual tumor was <0.5 cm in size. The breast response score was calculated based on the change in T-stage. For each decrease in T-stage, 1 point was awarded, except for the transition to T0. One point was awarded for the achievement of a near-pCR breast and 2 points for a pCR breast. For example, a patient with an initial 6-cm breast tumor, who was found to have a near-pCR breast at pathology examination after surgery, would have received 3 points (2 points for cT3 to T1 + 1 point for near pCR), whereas the maximum number of achievable breast response score for this patient would have been 4 (cT3 to T1 + 2 points for true pCR).
The axillary response score was calculated based on a simplified clinical staging system. The axillary stage at diagnosis was classified as cA3 when axillary (and/or periclavicular) nodes were palpable and proven to contain tumor cells, obtained by ultrasound-guided FNA. The stage was cA2 when there were no palpable nodes, but when ultrasound and FNA demonstrated tumor spread to the axilla. A cA1 stage was present when only the prechemotherapy sentinel node biopsy was tumor positive (at least micrometastatic disease, ‡0.2 mm in diameter) and cA0 stage if the sentinel node was tumor negative. After chemotherapy, pA3 disease was present when there remained at least one tumor-positive lymph node that had still been palpable at physical examination before surgery; pA2 stage was present if one or more nonpalpable nodes were shown to contain metastatic disease >2 mm in diameter in the axillary node dissection specimen; pA1 if the remaining lymph node metastases were microscopic only (<2 mm) and pA0 if no axillary tumor cells could be found. Again, 1 point was awarded for every decrease in stage. For example, a patient with initially palpable axillary node metastases who, at surgery, only had micrometastatic disease in the axilla would receive 2 points (cA3 to pA1). For this patient, the maximum number of achievable points would have been 3 (cA3 to pA0).
The NRI was defined as the sum of the breast response score and the axillary response score, divided by the sum of achievable points. Thus, in the example, the breast response score was 3 with 4 achievable points for the breast, and the axillary response score was 2 with 3 achievable points for the axilla. Consequently, the NRI would be (3 + 2)/(4 + 3) = 5/7. The division by the total number of achievable points ensures that the NRI is always ‡0 and £1. An NRI of 1 represents a pCR of both the breast and the axilla, while an NRI of 0 signifies the absence of any downstaging. A minor decrease in tumor size and/or axillary disease extent remains, however, compatible with an NRI of 0. Special rules were applied for a few exceptional situations. First, patients who discontinued neoadjuvant chemotherapy because of progression, or who had progression at the time of surgery were assigned an NRI of 0. Second, microscopic or even macroscopic axillary disease may rarely be found after chemotherapy despite an initially negative sentinel node biopsy. In such a case, the axillary response score is defined to be 0 (a no change situation is assumed to be present), but the number of achievable points for the axilla is considered to be 1 in case of microscopic disease and 2 in case of macroscopic disease. statistics SPSS statistics version 17.0 was used for all statistical calculations. Recurrence-free survival was calculated as the time between the first course of chemotherapy and the event. Events included the demonstration of metastatic disease, locoregional relapse or second tumor, or death in the absence of known disease.
Median NRI, interquartile range and pCR were calculated based on all patients and within various breast cancer subtypes separately. Differences were statistically tested using the Mann-Whitney U test for not normally distributed continuous variables and the Fisher's exact test for binary variables. Survival curves were plotted according to the method by Kaplan and Meier and differences between curves were tested with the log-rank test. A sensitivity analysis of the results was carried out by employing different relative weights of the breast response score and the axillary response score. All analyses were carried out using SPSS (Release 17.0.0; SPSS Inc., Chicago, IL). Table 1 .
Reasons for failure to calculate the NRI Reasons for failure to calculate the NRI were as follows.
Ten patients received substantially different chemotherapy than planned for various reasons and were excluded from the analysis. Three patients turned out to have stage IV disease and were excluded. Three patients had local relapses rather than primary tumors. In five patients with initially tumor-positive axillas, no axillary node dissection was done. Two further patients did not undergo surgery at all. In six patients the pathological response due to chemotherapy was not evaluable because of presurgery radiotherapy. In seven patients, the required data to calculate the NRI were missing in either the pathology report (two), the prechemotherapy axillary staging (one) or the postchemotherapy physical examination (four).
Technically, an NRI could be calculated in the large majority of patients, based on data extracted from the medical charts without the need for a separate pathology review. In only seven of the 303 patients (2%), missing data were the reason for not obtaining an NRI.
NRI values in different breast cancer subtypes
The average NRI for all 267 patients was 0.48 (median 0.40, range 0-1). Forty-one patients (15%) had an NRI of 0 and thus did not achieve any downstaging or even experienced progressive disease. A total of 55 patients (21%) had an NRI of 1, and thus achieved a pCR of both breast and axilla. The remaining patients, roughly two-thirds of all, achieved some degree of downstaging, as is graphically shown in a waterfall plot in Figure 1 .
pCRs are more frequently seen in patients with triplenegative tumors than in patients with ER+ HER2-negative (HER2) tumors. In addition, HER2+ tumors treated preoperatively with a trastuzumab-based regimen frequently achieve a pCR as well, particularly if they have negative hormone receptors. This higher degree of chemosensitivity is also reflected by a higher average NRI, as seen in Figure 2 .
As shown in Figure 2 , the ER+ HER22 tumors are less sensitive to chemotherapy in terms of pathological complete response rate than other breast cancer subtypes. Particularly for these tumors, which roughly correspond to the molecular subtype luminal, a more detailed response measure than that currently in use could be helpful to spare some patients chemotherapy.
relative weight of breast response versus axillary response
In some cases, a marked response of the breast tumor is observed, with little or no change in the axilla. In other patients, the axilla responds better than the breast. The weight given to the breast response versus that of the axillary response in the definition of the NRI is arbitrary. Due to the definition of the NRI, the relative weight assignments do not influence the NRI values of 0 and 1, but they may influence the intermediate NRI values. To study the impact of the relative weight of the two response values, we calculated an NRI-a2 (in which the weight of the axillary response was doubled) and an NRI-a0.5 in which the axilla weight was halved. For the whole group, the average NRI-a2 was 0.47 and the average NRI-a0.5 was 0.49 while the average original NRI was 0.48. No value of the NRI-a2 or NRI-a0.5 was >0.17 different from the NRI, and in only 15% of the patients was this difference >0.10. We conclude that assigning a higher or lower weight to the axillary response does not substantially affect the NRI.
trastuzumab-based preoperative chemotherapy
Preoperative chemotherapy with a concurrent trastuzumabbased regimen was introduced in August 2005 for tumors harboring HER2 amplification. Thirteen patients with HER2+ tumors began chemotherapy before this date and received ddAC, 57 patients started after this date and received a combination of trastuzumab, carboplatin and paclitaxel. The number of pCRs following ddAC was 0 and that after trastuzumab, carboplatin and paclitaxel was 29 (P < 0.001). The average NRI of the ddAC patients and the trastuzumab-treated patients were 0.52 and 0.73, respectively (P = 0.009). This comparison may be biased, however, as only two of the 13 patients who received ddAC had HER+ ER2 tumors, while 32 of the 57 tumors treated with trastuzumab, carboplatin and paclitaxel were ER negative (ER2). Following concurrent trastuzumab, in HER2+ ER+ tumors (N = 25), the average NRI was 0.59 (N = 25) with seven pCRs. For the HER2+ ER2 tumors, these values were 0.85 (N = 32) with 22 pCRs. The pCR rates differed substantially (P = 0.003) as did the NRI values (P = 0.002).
endocrine responsiveness and response
From a total of 128 ER+ HER22 tumors, both the NRI and the immunohistochemistry of ER and progesterone receptor (PR) were available. In this subtype of breast cancer, too few pCRs are observed to study an association between hormone receptor expression and relative resistance to chemotherapy. Using the NRI first, a possible predictive power of PR expression was studied ( Figure 3) . As expected, the number of pCRs was low in both the ER+ PR+ and the ER+ PR2 groups. There was a trend for more downstaging by chemotherapy in the ER+ PR2 group (NRI 0.38 versus 0.26 for the ER+ PR+ group), but this difference did not achieve statistical significance.
A second comparison was made between 'highly endocrine responsive' tumors and 'incompletely endocrine responsive' ones. Highly endocrine responsive tumors are defined as tumors in which both hormone receptors ER and PR are expressed in the majority of tumor cells [12] . The required data of 127 tumors were available for this analysis. The average NRIs were 0.22 and 0.35, for the highly and incompletely endocrine responsive tumors, respectively. This difference was statistically significant (P = 0.004, Figure 4) . The follow-up for this patient group is too short to determine any relationships with relapse-free or overall survival.
discussion
The NRI is a simple instrument to assess the degree of downstaging induced by preoperative systemic therapy in breast cancer. It requires information that is usually present in the charts of patients who received neoadjuvant chemotherapy in recent years. The only nonstandard data in the calculation is the result of the prechemotherapy sentinel node biopsy, which is not invariably obtained. If this is not available, a modified version of the NRI could easily be constructed that should yield similar results. As expected, the NRI in our study could be calculated from the large majority of patients, and in only seven patients this was not possible due to incomplete data in the medical chart. In all other cases, the NRI was not calculated because either the surgery required to establish the pathological response was not done or the presurgery treatment regimen had been so different that the results of a calculated NRI were considered to be noninformative. Thus, the use of the NRI is feasible in most situations.
The definition of the NRI was designed to obtain a maximum of replicability and a minimum of arbitrariness. For the breast response, reduction in T-stage was chosen rather than a decrease in geometrical volume, because the T-stage is universally accepted and available and because volume estimations strongly depend on technique and interpretation. In addition, any degree of shrinkage measured in two numbers beyond the decimal point would indicate a nonexistent precision. For the axillary Annals of Oncology original article response, the presence or absence of palpable lymph nodes is taken into account, although this is clearly a subjective observation. In practice, however, no other estimation of tumor mass in the axilla is routinely available. The relative weight assigned to the breast response and the axilla response has little effect on the NRI, as a sensitivity analysis confirmed. The definition of the NRI also ensures that the widely accepted response measure pCR (of both breast and axilla) is incorporated in a natural way as '1'. The NRI could be particularly useful in the breast cancer subtype that is sometimes referred to as luminal. Although this molecular classification was originally based on the results of a gene expression mRNA microarray [13] , the luminal breast group mainly comprises tumors that express the ER, but lack amplification of the HER2 gene [14, 15] (J. de Ronde et al., unpublished data). In this tumor group, which includes two-thirds of all breast cancers, pCRs are not usually achieved by preoperative chemotherapy, although the reduction in size of the primary tumor and the degree of downstaging may be substantial. It is unclear whether the degree of downstaging is prognostically important. It has been indicated that clinical response is not related to recurrence-free survival, but these conclusions are mainly derived from studies that did not distinguish between the molecular or immunohistochemical subtypes. As a result, the difference in outcome between the patients achieving a pCR and those who do not may largely reflect the effects in the ER2 subgroups, which includes the highly chemotherapy-sensitive group called 'triplenegative' or 'basal-like' breast cancer. This subgroup accounts for the large majority of the pCRs in these studies, and-paradoxically-also for the majority of the early relapses. This, and the inability to grade the chemotherapy response employing standard criteria, may have obscured any prognostic significance of tumor shrinkage.
In the luminal subgroup, pCRs are rare. In the present series, only seven of 129 patients (5%) achieved a pCR. It is clear that the ultimate goal of adjuvant chemotherapy, survival benefit, is not limited to the patients who achieved a pCR. Data from the Oxford overview [7] show that the reduction of odds of relapse in the ER+ group as a result of chemotherapy is 25% and this would lead to a >5% decrease in relapse rate in this group of high-risk patients. In addition, we have recently shown that a poor prognosis result of the 70-gene prognostic test (MammaprintÒ) is associated with a better response to chemotherapy in luminal tumors [16] and that the percentage of tumors in the neoadjuvant setting with a poor prognostic profile is 85% while this is only 50% in N0 disease [17] . Thus, the beneficial effect of chemotherapy may even be greater than this conservative estimate. Unfortunately, we cannot test this hypothesis in the series of patients reported here. Only two patients of the luminal subset had relapsed at the time this article was written, which is explained by the short median follow-up of the patient group, which is 28 months for the surviving patients, with a lead follow-up of 52 months. Whether the NRI will be of prognostic significance in luminal tumors and what values of the NRI should be regarded as 'good' and which ones as 'poor' in terms of recurrence-free and overall survivals could not yet be analyzed with this data set.
It is not surprising that different average values for the NRI were found in the different subtypes of breast cancer (Figure 2) . From studies using pCR as an end point, it was already clear that the pCR rate is high in triple-negative tumors, and even higher in HER2+ tumors when trastuzumab is used as part of the preoperative drug regimen [18, 19] . It is not obvious from the literature whether the ER2 HER22 tumors do even better than the HER2+ ER+ ones [20] . In our series, this is clearly the case and the difference is statistically significant, irrespective of whether the pCR rate or the NRI is used for the analysis. For the ER+ HER22 subgroup, expression of the PR has been indicated to be predictive of chemotherapy resistance, but the PR clearly lacks this predictive power in the Oxford metaanalysis. In our series, the NRI showed a tendency for less downstaging in the PR+ than in the PR2 tumors, but this difference was not statistically significant. It was, however, clear that tumors satisfying the criteria for 'high endocrine responsiveness' responded less well to chemotherapy than those considered to be 'incompletely endocrine responsive'. Importantly, however, some pCRs were even seen in the highly endocrine responsive group. Thus, even here, chemotherapy could have a modest role in the (neo)adjuvant setting.
The follow-up of our patients, who received their preoperative chemotherapy between 2004 and 2008, is too short to correlate the different NRI values with recurrence-free or overall survival. Only in the triple-negative group, a number of relapses were observed that allowed at least a preliminary original article Annals of Oncology analysis of this kind. In 65 assessable patients, 14 relapses were seen. Two of these occurred despite having obtained a pCR and both consisted of an isolated central nervous system relapse. The relapse rates in the pCR group and non-pCR group were not statistically different. When the NRI was employed, and an arbitrary cut-off value of 0.7 was used, the recurrence-free survival was substantially different between the resulting groups ( Figure 5) . Clearly, the validity of this cut-off value requires validation in independent studies. Even if it is confirmed, it may well apply to basal-like tumors and other NRI cut-offs may be optimal for other molecular subtypes.
In summary, we believe that studies evaluating the effect of neoadjuvant therapy should report the results separately for the subgroups that are defined by ER and PR expression and by the presence or absence of HER2 amplification. It is reasonable to express these results in pCR rates for the HER2-amplified tumors that do not express the ER, but a large deal of information is lost when lesser degrees of remission are not taken into account for the other subgroups. This is particularly true for the ER+ HER22 subtype, in which a pCR is achieved only rarely. The NRI as described here, or perhaps a slightly modified index to correct for the absence of prechemotherapy sentinel node information, could be quite useful to further classify these responses and to better reflect the efficacy of neoadjuvant systemic regimens than the binary pCR-no pCR system. This should, of course, be confirmed in independent series with long-term follow-up. references Figure 5 . Neoadjuvant response index (NRI) and relapse prediction in triple-negative breast cancer. A total of 65 patients with triple-negative breast cancer received preoperative chemotherapy. Nineteen patients achieved a complete response. Two of these relapsed, both with isolated central nervous system metastases. Twelve of the 46 noncomplete responders relapsed. Using a cut-off NRI level of 0.7, the NRI differentiated between a good prognosis group and a poor prognosis group (P = 0.03, log-rank test). There was no significant difference in T-stage or nodal status between the groups (data not shown). The recurrence-free survival difference between the pathological complete remission (pCR) and the non-pCR group was not statistically significant.
